Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Lead Product(s) : Tissue-engineered Autologous Outer Root Sheath Keratinocytes
Therapeutic Area : Cardiology/Vascular Diseases
Study Phase : Phase II
Sponsor : Healiva
Deal Size : Undisclosed
Deal Type : Acquisition
Healiva Acquires Two Wound-healing Cell Therapy Assets From Smith+Nephew
Details : The first asset, EpiDex®, is an autologous epidermal equivalent that provides a surgery-free approach to healing chronic venous leg ulcers (VLUs). The second asset, now named healiva®002, is an off-the-shelf allogeneic cell therapy.
Brand Name : Epidex
Molecule Type : Cell and Gene therapy
Upfront Cash : Undisclosed
June 01, 2022
Lead Product(s) : Tissue-engineered Autologous Outer Root Sheath Keratinocytes
Therapeutic Area : Cardiology/Vascular Diseases
Highest Development Status : Phase II
Sponsor : Healiva
Deal Size : Undisclosed
Deal Type : Acquisition
LOOKING FOR A SUPPLIER?
Reset All
